An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks

Trial Profile

An open label safety study of fosamprenavir/ritonavir (FPV/rtv (Telzir)) administered to HIV/HCV co-infected patients over 96 weeks

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2014

At a glance

  • Drugs Fosamprenavir; Ritonavir
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Jun 2012 Status changed from recruiting to discontinued as reported by European Clinical Trials Database.
    • 24 Aug 2011 This trial was prematurely ended in Ireland but is still ongoing in Spain, according to the European Clinical Trials database record.
    • 24 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top